Medication use in adults with attention deficit/hyperactivity disorder in a commercially-insured population in the United States

References

• Pary R, Lewis S, Matuschka PR, et al. Attention deficit disorder in adults. Ann Clin Psychiatry 2002;14:105-11
   PubMedGoogle Scholar
• Swanson JM, Sergeant JA, Taylor E, et al. Attention-deficit hyperactivity disorder and hyperkinetic disorder. Lancet 1998;351:429-33
   PubMed Web of Science ®Google Scholar
• Polanczyk G, Rohde LA. Epidemiology of attention-deficit/hyperactivity disorder across the lifespan. Curr Opin Psychiatry 2007;20:386-92
   PubMed Web of Science ®Google Scholar
• Kessler RC, Adler L, Barkley R, et al. The prevalence and correlates of adult ADHD in the United States: results from the National Comorbidity Survey Replication. Am J Psychiatry 2006;163:716-23
   PubMed Web of Science ®Google Scholar
• Polanczyk G, de Lima MS, Horta BL, et al. The worldwide prevalence of ADHD: a systematic review and metaregression analysis. Am J Psychiatry 2007;164:942-8
   PubMed Web of Science ®Google Scholar
• Goodman DW. The consequences of attention-deficit/hyperactivity disorder in adults. J Psychiatr Pract 2007;13:318-27
   PubMedGoogle Scholar
• Pohl GM, Van Brunt DL, Ye W, et al. A retrospective claims analysis of combination therapy in the treatment of adult attention-deficit/hyperactivity disorder (ADHD). BMC Health Serv Res 2009;9:95
   PubMed Web of Science ®Google Scholar
• Kooij SJ, Bejerot S, Blackwell A, et al. European consensus statement on diagnosis and treatment of adult ADHD: The European Network Adult ADHD. BMC Psychiatry 2010;10:67
   PubMed Web of Science ®Google Scholar
• Post RE, Kurlansik SL. Diagnosis and management of adult attention-deficit/hyperactivity disorder. Am Fam Physician 2012;85:890-6
   PubMed Web of Science ®Google Scholar
• Kendall T, Taylor E, Perez A, et al. Diagnosis and management of attention-deficit/hyperactivity disorder in children, young people, and adults: summary of NICE guidance. BMJ 2008;337:a1239
   PubMed Web of Science ®Google Scholar
• Castells X, Ramos-Quiroga JA, Bosch R, et al. Amphetamines for attention deficit hyperactivity disorder (ADHD) in adults. Cochrane Database Syst Rev 2011:CD007813
   PubMed Web of Science ®Google Scholar
• Banaschewski T, Roessner V, Dittmann RW, et al. Non-stimulant medications in the treatment of ADHD. Eur Child Adolesc Psychiatry 2004;13(Suppl 1):I102-16
   PubMedGoogle Scholar
• Mattes JA, Boswell L, Oliver H. Methylphenidate effects on symptoms of attention deficit disorder in adults. Arch Gen Psychiatry 1984;41:1059-63
   PubMed Web of Science ®Google Scholar
• Spencer T, Wilens T, Biederman J, et al. A double-blind, crossover comparison of methylphenidate and placebo in adults with childhood-onset attention-deficit hyperactivity disorder. Arch Gen Psychiatry 1995;52:434-43
   PubMed Web of Science ®Google Scholar
• Wilens TE, Morrison NR, Prince J. An update on the pharmacotherapy of attention-deficit/hyperactivity disorder in adults. Expert Rev Neurother 2011;11:1443-65
   PubMed Web of Science ®Google Scholar
• Olfson M, Blanco C, Wang S, et al. Trends in office-based treatment of adults with stimulants in the United States. J Clin Psychiatry 2013;74:43-50
   PubMed Web of Science ®Google Scholar
• Adler LA, Reingold LS, Morrill MS, et al. Combination pharmacotherapy for adult ADHD. Curr Psychiatry Rep 2006;8:409-15
   PubMedGoogle Scholar
• Adler L, Spencer TJ, Wilens TE. Attention-deficit hyperactivity disorder in adults and children. Cambridge: Cambridge University Press; 2015
   Google Scholar
• O’Connor PJ. Improving medication adherence: challenges for physicians, payers, and policy makers. Arch Intern Med 2006;166:1802-4
   PubMed Web of Science ®Google Scholar
• Kolar D, Keller A, Golfinopoulos M, et al. Treatment of adults with attention-deficit/hyperactivity disorder. Neuropsychiatr Dis Treat 2008;4:107-21
   PubMedGoogle Scholar
• Hodgkins P, Rahul S, Laura C, et al. Persistence, augmentation, and consumption of long-acting medications in ADHD patients. Am J Pharm Benefits 2012;4:149-58
   Google Scholar
• Charlson ME, Pompei P, Ales KL, et al. A new method of classifying prognostic comorbidity in longitudinal studies: development and validation. J Chronic Dis 1987;40:373-83
   PubMedGoogle Scholar
• Quan H, Sundararajan V, Halfon P, et al. Coding algorithms for defining comorbidities in ICD-9-CM and ICD-10 administrative data. Med Care 2005;43:1130-9
   PubMed Web of Science ®Google Scholar
• American Psychiatric Association. Task force on DSM-IV. Diagnostic and statistical manual of mental disorders: DSM-IV. 4th ed. Washington, DC: American Psychiatric Association; 1994
   Google Scholar
• Healthcare Cost and Utilization Project (HCUP). Elixhauser comorbidity software, Version 3.7 [Internet]. 2015. Available online at: http://www.hcup-us.ahrq.gov/toolssoftware/comorbidity/comorbidity.jsp. [Last accessed 6 June 2016]
   Google Scholar
• Cascade E, Kalali AH, Weisler RH. Short-acting versus long-acting medications for the treatment of ADHD. Psychiatry (Edgmont) 2008;5:24-7.
   PubMedGoogle Scholar
• Saloner B, Fullerton C, McGuire T. The impact of long-acting medications on attention-deficit/hyperactivity disorder treatment disparities. J Child Adolesc Psychopharmacol 2013;23:401-9
   PubMed Web of Science ®Google Scholar
• Spencer TJ, Mick E, Surman CB, et al. A randomized, single-blind, substitution study of OROS methylphenidate (Concerta) in ADHD adults receiving immediate release methylphenidate. J Atten Disord 2011;15:286-94
   PubMed Web of Science ®Google Scholar
• Ramos-Quiroga JA, Bosch R, Castells X, et al. Effect of switching drug formulations from immediate-release to extended-release OROS methylphenidate: a chart review of Spanish adults with attention-deficit hyperactivity disorder. CNS Drugs 2008;22:603-11
   PubMed Web of Science ®Google Scholar
• Srivastava K, Arora A, Kataria A, et al. Impact of reducing dosing frequency on adherence to oral therapies: a literature review and meta-analysis. Patient Prefer Adherence 2013;7:419-34
   PubMed Web of Science ®Google Scholar
• Swanson J. Compliance with stimulants for attention-deficit/hyperactivity disorder: issues and approaches for improvement. CNS Drugs 2003;17:117-31
   PubMed Web of Science ®Google Scholar
• Christensen L, Sasane R, Hodgkins P, et al. Pharmacological treatment patterns among patients with attention-deficit/hyperactivity disorder: retrospective claims-based analysis of a managed care population. Curr Med Res Opin 2010;26:977-89
   PubMed Web of Science ®Google Scholar
• Hodgkins P, Sasane R, Christensen L, et al. Treatment outcomes with methylphenidate formulations among patients with ADHD: retrospective claims analysis of a managed care population. Curr Med Res Opin 2001;27:53-62
   Google Scholar
• Lawson KA, Johnsrud M, Hodgkins P, et al. Utilization patterns of stimulants in ADHD in the Medicaid population: a retrospective analysis of data from the Texas Medicaid program. Clin Ther 2012;34:944-56 e4
   PubMed Web of Science ®Google Scholar
• Deyo RA, Cherkin DC, Ciol MA. Adapting a clinical comorbidity index for use with ICD-9-CM administrative databases. J Clin Epidemiol 1992;45:613-19
   PubMed Web of Science ®Google Scholar